New MIT Nanotech Fights Cancer Naturally
September 20, 2010 8:30 AM
comment(s) - last by
Harnessing the body's own defense forces to fight cancer with nanoscale technology.
In the myriad advances in treating cancer, many a nanotech study has crossed
path. This week another such study was revealed by the journal
(abstract). In the past, we’ve seen all sorts of man-made nanoparticles both acting as a force of cell destruction and as a ferry, shipping anti-tumor drugs straight to cancer cells where they can be of the most benefit. This latest method by Massachusetts Institute of Technology researchers is akin to the latter, but instead of using nanoparticles to deliver drugs, they deliver modified immune cells from the patient’s own body.
Dr. Darrell Irvine, the team leader for the MIT study, spoke optimistically of the new treatment. “What we're looking for is the extra nudge that could take immune-cell therapy from working in a subset of people to working in nearly all patients, and to take us closer to cures of disease rather than slowing progression.”
The process by which the treatment is administered
. T cells, a type of white blood cell which is involved in cell-mediated immunity, are harvested from the patient’s blood. They are then treated in such a way so that they specifically target cancer cells. The new T cells are then attached to a lipid-based nanoparticle filled with interleukins. Interleukins are a type of chemical that helps promote the growth of T cells. Finally, the T cell and interleukin-laden nanoparticles are injected back into the patient, where the T cells seek out the tumors they’ve been programmed to destroy. The interleukins help maintain a healthy T cell count to combat the cancer cells directly without causing aberrant production elsewhere in the body.
The final part here is important. Interleukin treatments have already been widely tested in cancer patients to promote cancer-fighting T cell growth, but the treatments can have devastating side effects including heart and lung failure. The targeted approach used by Irvine’s group holds the runaway T cell production process in check by only allowing those at the tumor’s area to be affected.
In a trial using mice, the treatment was found to be 100% effective. While standard T cell or T cell and interleukin treatment mice died after 75 days, the control mice died after only 25 days and the mice given the nanoparticle treatment lived on past the 100 day limit of the study.
This article is over a month old, voting and posting comments is disabled
RE: Pretty crappy side effect...
9/20/2010 9:26:01 AM
The article says the technique they used avoids this.
"We can't expect users to use common sense. That would eliminate the need for all sorts of legislation, committees, oversight and lawyers." -- Christopher Jennings
Nail Polish May Soon be Able to Detect Date Rape Drugs
August 26, 2014, 7:57 AM
SpaceX Falcon 9-R Rocket Suffers Malfunction, Self-Destructs During Test Flight
August 23, 2014, 9:36 AM
Texas Chosen as Site for SpaceX's First Commercial Launchpad
August 5, 2014, 1:44 PM
South Carolina Prison Finds Crashed Drone Carrying Drugs, Phones
August 1, 2014, 2:49 PM
NASA's Mars 2020 Rover Gains Seven New Instruments for Exploration
August 1, 2014, 1:30 PM
NASA Opportunity Rover Breaks Record for Most Miles Traveled on Another Planet
July 29, 2014, 1:38 PM
Most Popular Articles
HTC Preps Nexus 9 With Nvidia K1 64-Bit "Denver" SoC, Android L Onboard
September 10, 2014, 10:21 PM
Apple iPhone 6, iPhone 6 Plus Reviews Roll In
September 16, 2014, 9:13 PM
Big Media: If You Want Privacy, You're Probably a Pirate
September 18, 2014, 2:57 PM
Apple Cripples NFC in iPhone 6, 6+ With Developer Ban
September 17, 2014, 1:00 PM
"Decepticon" Driver Triumphs Over Cops in Massachusetts Court
September 5, 2014, 12:07 PM
Latest Blog Posts
ISIS Imposes Ban on Teaching Evolution in Iraq
Sep 17, 2014, 5:22 PM
Space Terrorism is a Looming Threat For the United States
Apr 23, 2014, 7:47 PM
Facebook Aims to Provide Internet to "Every Person in the World" with Drones, Satellites
Apr 1, 2014, 10:20 AM
Retail Mobile Sites Experience Outages in Light of Simplexity's Bankruptcy
Mar 14, 2014, 8:48 AM
Tesla vs. BMW: Who Has the Safer EV?
Feb 1, 2014, 2:56 PM
More Blog Posts
Copyright 2014 DailyTech LLC. -
Terms, Conditions & Privacy Information